Hook / Thesis
RxSight (ticker: $RXST) has been punished by headline risk and periodic adoption concerns, but operational data suggest the company is not in structural decline. Preliminary 2025 results showed full-year revenue of $134.5 million and a 12% increase in Light Adjustable Lens procedures to 109,615, while the installed base of Light Delivery Devices expanded to 1,134. After falling back to a 52-week low of $4.48 and trading near $4.94 today, the risk/reward looks asymmetric for a tactical long with firm stop discipline.
This trade idea is not a blind bottom call. It is a pragmatic buy-the-mean-reversion plan: the shares have already discounted a lot of bad news, the fundamentals show growth in procedures and LDD installs, and the valuation is modest relative to revenue. Technical indicators are neutral-to-mildly constructive (RSI ~43, MACD histogram positive), suggesting the stock can stage a bounce if adoption sentiment stabilizes.
What RxSight Does and Why It Matters
RxSight manufactures the Light Adjustable Lens and the Light Delivery Device used to customize intraocular lenses after cataract surgery. The product is a differentiated medtech offering because it allows post-operative refractive fine-tuning, which can improve visual outcomes and patient satisfaction compared with fixed IOLs. For the market, the key fundamental driver is adoption: procedure volume and the installed base of Light Delivery Devices (LDDs) drive recurring lens sales and revenue visibility.
Investors should care because the company reported preliminary 2025 revenue of $134.5M and a rise to 109,615 procedures, indicating continuing adoption despite the public controversy that pressured the stock in 2025. The installed base of 1,134 LDDs expands the serviceable market footprint and provides a foundation for recurring consumable lens revenue.
Support for the Bull Case - Numbers That Matter
- 2025 preliminary revenue: $134.5 million (announced 01/11/2026).
- Procedures: 109,615 Light Adjustable Lens procedures in 2025, up 12% year-over-year.
- Installed base: 1,134 Light Delivery Devices.
- Market cap: roughly $204.5 million at current pricing, with enterprise value near $192.7 million.
- Valuation signals: price-to-sales near the low-mid single digits (price_to_sales ~1.65; EV/sales ~1.51), which is modest for a growth-medtech company with recurring consumable economics.
- Balance sheet / liquidity: the company reports essentially $0.64 million in cash on hand in the latest snapshot, no debt (debt_to_equity 0), and strong short-term liquidity ratios (current ratio ~10.2, quick ratio ~8.93).
- Profitability: EPS is negative (roughly -$1.13 last reported), and free cash flow is negative (~-$21.6 million), so the company is still burning cash while growing top line.
Valuation Framing
At a market cap of about $204.5M and revenue of $134.5M, RxSight trades at roughly 1.5x EV/sales. For a medtech company with a differentiated consumable and a growing installed base, that multiple is reasonable and arguably conservative, especially given the growth in procedures. The company is not profitable today (EPS -$1.13; negative FCF), so classic earnings multiples are not meaningful, but the revenue multiple suggests investors are pricing in slower adoption or continued headline risk.
Compare this informally to earlier trading ranges: the 52-week high of $13.22 implies investors were willing to pay materially more for the story when sentiment was improved. The current multiple gives a margin of safety for mid-term mean reversion if adoption and guidance cadence remain steady or improve.
Technical Setup
- Current price: $4.94 (intraday snapshot).
- 10-day SMA: ~$5.26, 20-day SMA: ~$5.08, 50-day SMA: ~$5.53 - price is below the short- and medium-term moving averages, so this is a contrarian buy against the near-term trend.
- RSI is ~43.6 (neither oversold nor overbought) and MACD histogram is slightly positive, indicating bullish momentum beginning to build but not yet decisive.
- Short interest and short volume have been elevated in recent weeks (days-to-cover has fallen to ~3.9), which can amplify moves in either direction.
Trade Plan (Actionable)
Entry: Buy at $4.95.
Stop loss: $4.40 - a clean technical level below the recent 52-week low area and intraday ranges, to cap downside in a headline-driven stock.
Target: $7.00 - this represents a sensible mid-term objective that captures a rebound toward prior moving averages and partial multiple expansion while still being realistic given the company size and 52-week high. If momentum is stronger, consider scaling into a second target near $9.50 as a stretch goal.
Time horizon: mid term (45 trading days). I expect this trade to play out over the next several weeks to 45 trading days if headlines stabilize and procedure volume commentary remains positive. If adoption accelerates meaningfully, the position can be extended or re-rated to a longer-term position, but treat this plan as a tactical swing trade to exploit mean reversion.
Position sizing: given headline risk and low cash on hand, limit initial position size to a small percentage of capital (e.g., 1-2% of portfolio capital), and consider layering if catalysts confirm the thesis.
Catalysts
- Regular quarterly/annual reporting that confirms stable or accelerating procedure growth and revenue (next results cadence will be important).
- Management commentary and guidance cadence under the new CFO (appointed 01/11/2026) that restore confidence in forecasting and controls.
- Installation momentum: continued growth in the installed base of LDDs and rising consumable lens sales per device.
- Resolution or cooling of outstanding litigation headlines related to the 2025 investor lawsuits; any favorable legal developments would remove a major overhang.
Risks and Counterarguments
- Operational execution risk: The company is still unprofitable (EPS ~ -$1.13) and negative FCF (~ -$21.6M). Continued cash burn without clear path to positive FCF or profitability would pressure multiples and share price.
- Balance sheet concerns: Cash on hand is reported at only about $0.64M. Despite no debt, such low cash raises questions about near-term liquidity flexibility; management may need to raise capital if cash burn continues, which could dilute equity holders.
- Regulatory and litigation overhang: The company faced multiple class action investigations and negative publicity in 09/2025. Ongoing legal scrutiny and potential settlements could be costly and keep sentiment depressed.
- Adoption risk: The bull case depends on continued uptake of LDDs and procedures. If procedure growth stalls or declines, revenue and valuation would likely suffer further.
- Counterargument: The market may be right to apply a discounted multiple because early uptake, reimbursement dynamics, or competitor moves could compress the long-term addressable market for adjustable IOLs. If the company's product does not achieve the anticipated durable preference among surgeons and patients, the story could deteriorate further.
What Would Change My Mind
I will become constructive on a larger, multi-quarter position if management can demonstrate sustained revenue growth with improving gross margins, clear guidance that narrows the range, and materially larger cash on hand or positive free cash flow. Conversely, a meaningful sequential decline in procedure growth, a costly legal settlement, or a dilutive capital raise would make me close the position and likely turn bearish.
Conclusion
RxSight is a tactical buying opportunity for disciplined traders willing to accept headline risk. The company reported meaningful revenue and procedure growth last year, yet the stock trades at a conservative revenue multiple and sits near a 52-week low. That combination creates an asymmetric trade if you control downside with a strict stop. For traders who want a defined-risk swing trade with mid-term upside, buying at $4.95 with a stop at $4.40 and a target of $7.00 is a reasonable plan. Keep position size modest, monitor procedure growth and legal headlines closely, and be prepared to exit quickly if fundamentals deteriorate.